




ALSRP Award Mechanisms Build A Therapeutic Pipeline




Therapeutic Idea Award \$600,000 / 3 years

- Supports highly innovative, hypothesis-driven preclinical therapeutic development in ALS.
- Proof-of-concept drug discovery.
- Preliminary data are not required.



Therapeutic Development Award \$1,500,000 / 3 years

- Investigational New Drug (IND)-enabling.
- Preliminary data are required, including therapeutic efficacy in at least one ALS-relevant model system.



Pilot Clinical Trial Award \$2,000,000/4 years

- Early phase intervention trials, must include biomarker data.
- Preliminary data are required.
- Inform and de-risk more advanced future trials for the treatment or management of ALS.

New for FY24! Applications must address one focus area:

- Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific predictive, efficacy, and/or pharmacodynamic biomarkers.
- Clinical Care: Improving aspects of clinical care and symptom management for Amyotrophic Lateral Sclerosis.



Clinical Outcomes and Biomarker Award \$750,000 / 3 years

- Development and improvement of clinical biomarkers to enrich clinical trials.
- Biomarker analysis can be therapeutic- or ALS subtype-specific, does not have to broadly apply to all patients.

